Transverse myelitis, a rare inflammatory disease characterized by spinal cord inflammation, is on the rise globally. The condition, which damages the myelin sheath covering nerve cell fibers, presents with various symptoms such as pain, weakness in limbs, abnormal sensations, and bladder and bowel problems. While the exact cause of transverse myelitis remains unknown, studies suggest that it can be triggered by multiple sclerosis, autoimmune disorders, Devic’s disease, and gastrointestinal tract infections.
Get a Sample Copy https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=56202
Complications associated with transverse myelitis include sexual dysfunction, stiffness, painful spasms, depression, and anxiety. Diagnosis typically involves a thorough medical history review and tests such as lumbar puncture, blood tests, and magnetic resonance imaging (MRI).
The global transverse myelitis treatment market is expected to witness significant growth in the coming years, driven by the increasing prevalence of the condition worldwide. Governments’ growing prioritization of drugs for rare disorders is also anticipated to propel market growth. However, the shortage of healthcare experts in Latin America and the Middle East & Africa poses a challenge to market expansion in these regions. Nonetheless, the market is likely to benefit from increased government funding for diagnostic procedures.
Several organizations are actively supporting the treatment of transverse myelitis on a global scale, including the Genetic and Rare Diseases (GARD) Information Center, the NIH/National Institute of Neurological Disorders and Stroke, the Academy of Spinal Cord Injury Professionals, Inc., and the Transverse Myelitis Association.
The global transverse myelitis treatment market can be segmented based on treatment, end-user, and region. Treatment options include drugs (such as intravenous steroids, antiviral medication, and pain medication) and therapies (including physical therapy, occupational therapy, and psychotherapy). Methylprednisolone and dexamethasone are commonly used steroids for transverse myelitis treatment, while occupational and physical therapy have shown effectiveness in some patients. Chronic pain, a common complication, is often managed with over-the-counter pain relievers like acetaminophen, naproxen, and ibuprofen.
Hospitals, special clinics, and other healthcare facilities serve as the primary end-users of transverse myelitis treatment. In 2017, hospitals accounted for a significant share of the market.
Geographically, North America led the global transverse myelitis treatment market in 2017, followed by Europe and Asia Pacific. The United States held a substantial revenue share within North America. The Asia Pacific region is experiencing rapid market growth due to an increasing number of transverse myelitis patients, improved healthcare infrastructure, economic growth, expanding private healthcare sector, and rising awareness about transverse myelitis treatment. Latin America and the Middle East & Africa are projected to witness moderate growth rates from 2018 to 2026.
Key players operating in the global transverse myelitis treatment market include Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., WOCKHARDT, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Baxter, Amerigen Pharmaceuticals Limited, and Novartis AG.